Background: The GeparQuinto study showed that adding bevacizumab to 24 weeks of anthracycline-taxane-based neoadjuvant chemotherapy increases pathological complete response ( pCR) rates overall and specifically in patients with triple-negative breast cancer (TNBC). No difference in pCR rate was observed for adding everolimus to paclitaxel in nonearly responding patients. Here, we present disease-free (DFS) and overall survival (OS) analyses.
treatment according to this interim response [2] . Patients with a complete or partial interim response are more treatment sensitive and therefore more likely to achieve a pathological complete response (pCR) at surgery [3] ; however, patients without an interim response are considered chemotherapy resistant as they rarely achieve a pCR even after a switch to a noncross-resistant chemotherapy regimen [4] . Therefore, separate treatment strategies might be developed for these patient populations. The GeparQuinto phase III study investigated subtype-specific treatment approaches for newly diagnosed, untreated patients with HER2-negative breast cancer [5] , HER2-negative breast cancer without response to four cycles of NACT [6] and HER2-positive breast cancer [7] . This report focuses on patients with HER2-negative, tumors who were treated with sequential epirubicin/cyclophosphamide and docetaxel (EC-T) NACT and randomized to simultaneous treatment with bevacizumab or no additional therapy or were re-randomized to paclitaxel with or without everolimus if they did not respond to EC [5, 6] . pCR rates increased from 14.9% with EC-T alone to 18.4% with EC-T and bevacizumab [odds ratio = 1.29; 95% confidence interval (CI) 1.02-1.65; P = 0.042] and the effect on pCR was more pronounced in patients with triple-negative breast cancer (TNBC; 27.9% and 39.3%; P = 0.003) [8] . Chemotherapy with bevacizumab was associated with a higher incidence of grade 3/4 toxicities [5] . Only 18 (4.6%) of 403 patients nonresponsive to EC achieved a pCR; 7 (3.6%) treated with paclitaxel and everolimus and 11 (5.6%) treated with paclitaxel alone [odds ratio (OR) 0.36; 95% CI 0.24-1.6; P = 0.34]. Mucosal inflammation, thrombocytopenia, neutropenia, infection and skin rash were more frequent when everolimus was added to paclitaxel [6] .
As the required number of relapses or deaths has recently been reached for the HER2-negative cohort, we here report the corresponding survival analyses. Survival analyses of the patients with HER2-positive tumors are planned for 2015 when the required number of events is observed.
patients and methods objectives
The primary efficacy end point for both randomized treatment comparisons of patients with HER2-negative breast cancer was pCR, which has been reported earlier together with the related toxicity [4, 5] . We here report secondary objectives of the study comparing survival of the treatment groups using disease-free (DFS), local recurrence-free (LRFS), locoregional recurrence-free (LRRFS), regional recurrence-free (RRFS), distant disease-free, 
selection of patients
Female patients with previously untreated, unilateral or bilateral, histologically confirmed invasive, nonmetastatic breast carcinoma were enrolled in the study if they provided written informed consent. Patients with any stage of disease deemed to be appropriate for chemotherapy were eligible (e.g. locally advanced tumors with cT4 or cT3, hormone-receptor-negative tumors or hormone-receptor-positive tumors with cN+ (for cT2) or pN SLN+ (for cT1) disease). HER2 status of the tumor had to be negative by HercepTest™ (Dako-score 0 or 1+) or in situ hybridization (Dako-score 2+ and no gene amplification) by the local pathologist. Tumor lesions were required to have a palpable size of ≥2 cm or a sonographical size of ≥1 cm in maximum diameter and had to be measurable in two dimensions, preferably by sonography.
treatment
All patients were scheduled to receive four cycles of EC (epirubicin 90 mg/ m 2 , cyclophosphamide 600 mg/m 2 , day 1, every 3 weeks) followed by four cycles of T (docetaxel 100 mg/m 2 , day 1, every 3 weeks). Patients were randomized to receive bevacizumab 15 mg/kg i.v. every 3 weeks starting on day 1 of the first EC cycle or no additional treatment. In patients without a sonographical or clinical response to four cycles of EC ± bevacizumab treatment was stopped if applicable and patients were randomized to weekly paclitaxel given on days 1, 8, 15 , every 3 weeks with 80 mg/m 2 over four cycles with or without everolimus given orally in a dose of 5 mg per day from day 13 after a dose-escalation starting from 2.5 mg every other day to 5 mg every day. In cases of tumor progression, study treatment was discontinued and further local and/or systemic treatment was permitted at the discretion of the investigator. Patients had to undergo surgery at least 28 days after the last chemotherapy or bevacizumab infusion. Recommended postoperative treatment consisted of radiotherapy to the ipsilateral remaining breast for all patients treated by breast conserving surgery and radiotherapy to the chest wall with or without regional nodes in case of mastectomy for patients with an initial tumor size >5 cm or clinically suspect axillary nodes before treatment or histologically involved nodes after neoadjuvant treatment. Endocrine treatment was given for at least 5 years in patients with HR-positive (≥10% stained cells for estrogen and/or progesterone receptor) tumors. No bevacizumab was given after surgery. Six monthly visits or telephone contacts were scheduled for at least 5 years to collect information on disease status. assessment of end points DFS (invasive) was defined as time from randomization or histological diagnosis in those patients not being randomized for the bevacizumab question until any invasive locoregional, invasive contralateral or distant recurrence of breast cancer or any second primary invasive nonbreast cancer or death due to any cause [9] . Events counted for LRFS were any local, i.e. ipsilateral invasive or ductal in situ recurrence of the ipsilateral breast; for LRRFS any local or regional, i.e. local or regional lymph node recurrences or any invasive contralateral breast cancer; for RRFS any local, regional or chest wall recurrences; and for OS death of any cause. During NACT, local progression of the breast tumor was not considered as a relapse. Patients without event were censored at the date of last contact.
Response to neoadjuvant treatment was assessed by physical examination, ultrasound and/or mammography and/or MRI before surgery as described previously [4] .
Pathologic response was assessed locally by examining all surgically excised breast and axillary lymphatic tissue according to TNM classification. pCR was defined as pT0 ypN0. Pathology reports were centrally reviewed at GBG headquarters.
End of treatment with the experimental compounds was defined as 4 weeks after last application. Thereafter, adverse events were not any longer recorded.
statistics
The GeparQuinto study was an open label, randomized phase III trial with pCR as the primary end point. Allocation to chemotherapy with or without target treatment was carried out by central randomization with a 1 : 1 ratio each and a stratification according to participating site, ER/PgR status (ER or PgR positive versus ER and PgR negative), extent of disease (T4 or N3 versus T1-3 and N0-2) and pretreatment with bevacizumab or not (only for everolimus). Assumptions for sample size calculation have published previously [4, 5] .
All analyses were carried out on an intent-to-treat approach including all patients having received one cycle EC for the bevacizumab question and all patients having received one course of paclitaxel for the everolimus question ( Figure 1) .
Survival analysis for the bevacizumab randomization was planned after 379 events observed to show a hazard ratio (HR) of 0.75 between the treatment arms using a two-sided α of 0.05 and 1 − β of 0.2. As the number of patients randomized for the everolimus question was considered too low for confirmative results, it was planned to run this analysis at the same time with the bevacizumab analysis. Time-to-event outcome parameters were estimated using the Kaplan-Meier product-limit method and treatment groups were compared using the log-rank test. Univariate Cox proportional hazards models Figure 1) . No clinical response after EC treatment was observed in 371 patients who were therefore allocated for the everolimus question (nonresponding cohort). This number was lower than expected. Therefore, the study protocol was amended after the completion of recruitment for the bevacizumab question. Then patients, who received 4 cycles of EC before entering the protocol and who did not respond were allowed to be randomized for the everolimus questions. Despite this amendment, recruitment to complete the nonresponder arm was poor (recruitment of additional 32 patients) and it appeared impossible to recruit the required 566 patients. Therefore, accrual was prematurely closed in June 2011 with 403 patients randomized into nonresponding cohort (Figure 1 ). After completion of chemotherapy and surgery, 390 relapses and 229 deaths overall and 112 relapses and 73 deaths in the nonresponding cohort were observed after a median follow-up of 3.8 years.
Baseline characteristics of patients were well balanced between treatment groups as previously shown (Table 1 ) [4, 5] . There was no statistically significant difference neither in DFS nor OS for patients receiving bevacizumab or not together with or after anthracycline-taxane-based chemotherapy (P = 0.7837 for DFS and P = 0.8422 for OS). Two hundred two and 195 events occurred with and without bevacizumab ( Figure 2 , Table 2 ). The HR was 1.03 (95% CI 0.84-1.25) for DFS and 0.97 (95% CI 0.75-1.26) for OS, the adjusted HR from multivariate analysis was 1.11 (95% CI 0.91-1.36) for DFS and 1.06 (95% CI 0.82-1.38) for OS. Similarly, no difference in LRFS, LRRFS and RFS was observed between the bevacizumab treatment arms (Table 2) . CDFS in patients with TNBC was not different between randomized arms (HR 0.95; 95% CI 0.56-1.62). Subgroup analysis ( Figure 4A ) could not identify a subgroup for which an effect of bevacizumab on DFS might be postulated. In opposite, patients with a pCR after neoadjuvant treatment showed a trend toward a higher risk for an event if they have received bevacizumab with a HR of 2.02 and a lower 95% CI However, the test for interaction was not significant with P = 0.067). Similar results were obtained for OS (supplementary Figure S1A , available at Annals of Oncology online). Comparing DFS and OS in patients not responsive to EC and treated with paclitaxel with or without everolimus, no statistically significant difference was found (P = 0.9870 for DFS and P = 0.657 for OS) (Figure 3) . The adjusted survival analysis revealed an HR of 1.13 (95% CI 0.77-1.65) for DFS and a HR of 1.24 (95% CI 0.77-2.40) for OS (Table 2) . Similarly, no difference in LRFS, LRRFS and RFS was observed between the bevacizumab treatment arms (Table 2 ). Subgroup analysis ( Figure 4B ) could not identify any subgroup for which an effect of everolimus on DFS might be postulated. Similar results were obtained for OS except for patients pretreated with bevacizumab which showed a higher risk of death when treated with everolimus (supplementary Figure S1B , available at Annals of Oncology online).
discussion
Survival analysis of the GeparQuinto study showed that neither bevacizumab nor everolimus improved survival when given simultaneously to NACT for 24 or 12 weeks, respectively. Whereas these results were expected for everolimus due to its inert effect on pCR, a positive outcome was awaited based on the effect of bevacizumab on pCR. Several hypotheses can be formulated to explain this dissociation of pCR and its effect on survival. The absolute improvement of pCR induced by bevacizumab was only 3.5%. The size of the study was far too small to show a survival effect resulting from those additional 32 patients with a pCR after bevacizumab and a potential switch from a more unfavorable outcome to a more favorable outcome. Despite the absolute difference of pCR rates in patients with TNBC being 11.4%, again only 32 additional patients achieved a pCR. Considering that only one-third of patients had TNBC, statistical power is even lower to show a survival difference. It is ever more of concern that patients with pCR showed a tendency toward a worse outcome when treated with bevacizumab in a way that a pCR induced by chemotherapy and bevacizumab seems less durable than those induced by chemotherapy alone. Such a potential negative rebound effect of bevacizumab was postulated previously e.g. in colon cancer [10] .
Survival results of GeparQuinto are in line with those reported from two large adjuvant studies E5103 and BEATRICE randomizing unselected or only patients with TNBC to chemotherapy with or without bevacizumab [11, 12] The NASBP B-40 study has some important differences compared with GeparQuinto that might provide further insight into this hypothesis [12] . Bevacizumab was given for only 18 weeks together with NACT, but was restarted after surgery to complete 1 full year of treatment. Effect of bevacizumab was observed mainly in hormone-receptor-positive/HER2-negative tumors, but with only 1206 patients randomized the statistical power of the study is probably too low as well to demonstrate surrogacy of pCR for survival.
In fact, a recent German [13] and an extended global metaanalysis of individual data of 11 955 patients from 11 trials could not prove surrogacy of pCR for survival [14] . Only the NOAH study reported an absolute improvement of pCR by 20% when trastuzumab was added to NACT for patients with HER2-positive disease and found this to be predictive for a prolonged better outcome of the trastuzumab-treated patients [15] .
Based on our findings, the new registration pathway recently announced by FDA and EMA has to be used with caution. Effect of the new compound on pCR must be substantial (e.g. more than absolute 20%) and there should be certainty that survival data will become available within reasonable time.
Evaluation of the everolimus effect might not be final as current duration of follow-up of this phase II GeparQuinto study is still short and delayed treatment effects, especially in the hormone-receptor-positive cohort, cannot be excluded. However, despite the dose of everolimus in combination with chemotherapy was lower than the approved dose in combination with letrozole (5 versus 10 mg), the higher toxicity of this regimen will make a substantial effect on survival mandatory which even at this early point of observation is highly unlikely.
In conclusion, results of the GeparQuinto study do not support the use of bevacizumab or everolimus in the neoadjuvant setting in addition to an anthracycline-taxane-based chemotherapy.
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